On June 13, WuXi PharmaTech's wholly-owned subsidiary, PharmaTech, was successfully listed on the Hong Kong Stock Exchange. The opening price was HK$25.00. As of the close of the morning, the closing price was HK$27.950. According to the announcement of Yaoming Biological, the offer price was set at HK$20.6 per share, and the proposed issuance of 192,298,500 shares, raising a total of HK$3.975 billion. Out of the box, the performance is growing rapidly Pharmacological organism is not only an important subsidiary of WuXi PharmaTech, but also the largest biologics research and development service provider in China. In 2014, PharmaTech's biological decoction drug Mingkang was registered as an independent company. Prior to this, Pharmacy's biologics business together with Small molecules, cellular gene therapy, medical devices and genomics are among the five unique business units of WuXi PharmaTech. After its independence, Wuming Bio provides a comprehensive range of services related to the discovery, development and production of biologics. The business covers a total of five phases: drug discovery, preclinical development, early (stage I and II) clinical Development, late (phase III) clinical development and commercial production, the partners include 12 of the current global TOP20 pharmaceutical companies. Business provided by Yaoming Biological At present, PharmaTech has three operating bases in Wuxi, Shanghai and Suzhou, and operates through six subsidiaries, including Wuxi Biotechnology, Suzhou Testing, Shanghai Biotechnology, HK Biologics, US Biologics and UK Biologics. The three operating bases of Yaoming Biological Among them, facilities in Wuxi and Shanghai are designed according to global regulatory standards and comply with international GMP regulations, which enables them to simultaneously promote the development and registration of innovative biological agents and biosimilars in China and overseas markets. According to the Frost & Sullivan Report, PharmaTech is running one of the world's best cell culture development laboratories, with more than 260 bioreactors with independent capacities ranging from 1 liter to 200 liters. At the same time, Yaoming Bio has formed an experienced development team in the global biologics industry. As of December 31, 2016, the team consisted of 732 scientists, of whom 475 had a master's degree and 114 had a doctorate. These talent resources are the advantages that Yaoming Biotechnology relies on for growth. Urinary and Reproductive System silicone foley catheter,foley catheter with temperature sensor,hsg catheter,cervical ripening balloon Anesthesia Medical Co., Ltd. , https://www.jssinoanesthesias.com
